口服祛痰药市场 - 按药物类型、剂型、药物、配销通路- 全球预测

由于全球气喘、慢性支气管炎和COPD（慢性阻塞性肺病）等呼吸系统疾病的盛行率不断上升，口服祛痰药市场规模预计在2024 年至2032 年期间复合年增长率将达到创纪录的3.4 %。根据世界卫生组织的数据，目前全球有 3.92 亿人患有慢性阻塞性肺病。这些情况可能会引起咳嗽和产生黏液等症状，进一步增加了对口服避孕药作为常见治疗选择的需求。此外，由于空气污染、吸烟和生活方式的改变，呼吸系统疾病的风险不断增加，有利于产品的采用。

随着人口老化的加剧和呼吸系统疾病的增加，对口腔呼吸器的需求日益加剧。医疗保健基础设施的快速进步以及药房和线上平台上非处方药（OTC）的可用性的提高也将为获得口服前景提供机会，从而支持市场成长。

口腔祛痰药产业分为药物类型、剂型、用药、配销通路和区域。

根据药物类型，黏液溶解剂领域的市场规模在2024年至2032年间将录得3.1%的成长率，因为它能有效治疗慢性支气管炎和囊性纤维化等以黏液黏稠为特征的呼吸道疾病。黏液溶解剂有助于稀释和鬆弛黏液分泌物，使人们在咳嗽时更容易清理呼吸道。这种操作方法还可以减少胸闷和呼吸困难等症状，增加患者对黏液溶解剂的需求，同时为医疗专业人员提供建议。

就配销通路而言，预计2024年至2032年，线上药局领域的口服祛痰药市场复合年增长率将达到2.9%，这得益于消费者可以方便地获得各种祛痰药物。随着感染和呼吸道疾病（例如咳嗽和流鼻涕）的增加，口腔诊所可以帮助患者轻鬆获得非处方祛痰产品。此外，药剂师更常提供有关适当祛痰剂选择的建议和指导将增加消费者的信心和产品的使用。

至2032年，由于都市化、工业化和环境污染，亚太地区口服祛痰药产业规模将以4%的复合年增长率持续成长。人口众多、呼吸健康意识不断增强以及医疗保健服务的普及将推动产品的采用。可满足区域需求和监管系统的各种口服祛痰剂配方也促进了亚太地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 呼吸道疾病盛行率增加
    • 对非处方药的需求不断增长
    • 老年人口不断增加
    • 提高人们对呼吸系统疾病的认识
  • 产业陷阱与挑战
    • 严格的政府和监管指南
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

• 主要趋势
• 分泌促进剂
  • 柠檬酸钾
  • 碘化钾
  • 柠檬酸钠
  • 癒创甘油醚
  • 氯化铵
  • 其他分泌促进剂
• 黏液溶解剂
  • 溴己新
  • 氨溴索
  • 乙酰半胱氨酸
  • 羧甲司坦神经氨酸

第 6 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 口服固体製剂
  • 粉末及颗粒
  • 药片
  • 胶囊
• 口服液
  • 糖浆
  • 解决方案
  • 暂停
• 吸入剂

第 7 章：市场估计与预测：按药物分类，2021 - 2032 年

• 主要趋势
• 处方药
• 非处方药物

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售店和药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• Abbott Laboratories
• AstraZeneca
• Cipla Inc.
• Genexa Inc.
• GlaxoSmithKline (GSK) plc
• Merck KGaA
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• The Himalaya Drug Company

Oral expectorant market size is set to record 3.4% CAGR from 2024 to 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic bronchitis, and COPD (Chronic Obstructive Pulmonary Disease) worldwide. As per WHO, currently 392 million people suffer from COPD worldwide. These conditions can cause symptoms like cough and mucus production, further increasing the need for oral contraceptives as a common treatment option. Moreover, the risk of respiratory diseases is increasing due to air pollution, smoking and lifestyle changes, favoring the product adoption.

With the growing aging population and increasing respiratory diseases, the need for oral ventilators is intensifying. Rapid advancements in healthcare infrastructure and higher availability of over the counter (OTC) drugs in pharmacies and online platforms will also provide opportunities to access oral prospects, supporting the market growth.

The oral expectorant industry is segmented into drug type, dosage form, medication, distribution channel, and region.

Based on drug type, the market size from the mucolytics segment will record 3.1% growth rate between 2024 and 2032, due to its efficiency in treating respiratory conditions characterized by thick and tenacious mucus, such as chronic bronchitis and cystic fibrosis. Mucolytics help thin and loosen mucous secretions, making it easier for people to clear their airways when they cough. This method of operation also reduces symptoms, such as chest congestion and dyspnea for increasing the patients need for mucolytics while providing recommendations for healthcare professionals.

With regards to distribution channel, the oral expectorant market from the online pharmacies segment is anticipated to witness 2.9% CAGR from 2024-2032, favored by convenient access to a wide range of expectorant medications for consumers. With the increase in infections and respiratory diseases, such as cough and runny nose, oral medicine clinics help in providing patients with easy access to over-the-counter expectorant products. Furthermore, increased availability of pharmacists for advice and guidance on appropriate expectorant choices will increase consumer confidence and product use.

Asia Pacific oral expectorant industry size will record sustained growth at 4% CAGR through 2032, attributed to urbanization, industrialization, and environmental pollution. Large population, increasing awareness about respiratory health and strong access to healthcare services will drive the product adoption. The wide variety of oral expectorant formulations available to meet regional needs and regulatory systems is also contributing to the market growth in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory disease
    • 3.2.1.2 Growing demand for OTC medications
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Increasing awareness among people about respiratory conditions
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Strict government and regulatory guidelines
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Secretion enhancer
  • 5.2.1 Potassium citrate
  • 5.2.2 Potassium iodide
  • 5.2.3 Sodium citrate
  • 5.2.4 Guaiphenesin
  • 5.2.5 Ammonium chloride
  • 5.2.6 Other secretion enhancer
• 5.3 Mucolytics
  • 5.3.1 Bromhexine
  • 5.3.2 Ambroxol
  • 5.3.3 Acetyl cysteine
  • 5.3.4 Carbocisteineurine

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral solids
  • 6.2.1 Powder & granules
  • 6.2.2 Tablet
  • 6.2.3 Capsule
• 6.3 Oral liquids
  • 6.3.1 Syrup
  • 6.3.2 Solution
  • 6.3.3 Suspension
• 6.4 Inhalants

Chapter 7 Market Estimates and Forecast, By Medication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription drugs
• 7.3 Over-the-counter drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail store & drug store
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AstraZeneca
• 10.3 Cipla Inc.
• 10.4 Genexa Inc.
• 10.5 GlaxoSmithKline (GSK) plc
• 10.6 Merck KGaA
• 10.7 Perrigo Company plc
• 10.8 Reckitt Benckiser Group PLC
• 10.9 Sanofi
• 10.10 Sun Pharmaceutical Industries Ltd.
• 10.11 The Himalaya Drug Company